Approximately 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 and a significantly greater PASI 75 response versus placebo was observed as early as week 4. The safety and tolerability profile remained consistent with prior studies.

The Latitude Phase 3 psoriasis studies are global, multicenter, randomized, double-blind, placebo- and active comparator-controlled studies to evaluate the efficacy, safety and tolerability of zasocitinib in adult patients with moderate-to-severe plaque psoriasis (PsO). These new data show that once-daily oral zasocitinib demonstrated rapid and durable skin clearance.